LFG Wealth Partners LLC Takes Position in Eli Lilly and Company $LLY

LFG Wealth Partners LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY) in the fourth quarter, Holdings Channel reports. The fund bought 2,218 shares of the company’s stock, valued at approximately $2,384,000. Eli Lilly and Company comprises 1.5% of LFG Wealth Partners LLC’s portfolio, making the stock its 21st biggest holding.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. Norges Bank bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $12,976,634,000. Capital Research Global Investors grew its position in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after acquiring an additional 4,332,008 shares during the period. Cardano Risk Management B.V. grew its position in shares of Eli Lilly and Company by 876.1% during the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock valued at $2,552,419,000 after acquiring an additional 2,131,734 shares during the period. Vanguard Group Inc. boosted its holdings in Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the period. Finally, Amundi boosted its holdings in Eli Lilly and Company by 27.1% in the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after buying an additional 964,675 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,130.12 on Tuesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.06 trillion, a PE ratio of 40.15, a P/E/G ratio of 1.24 and a beta of 0.53. The company’s 50 day simple moving average is $1,002.35 and its two-hundred day simple moving average is $1,016.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the company posted $3.34 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were paid a $1.73 dividend. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

Several research firms recently commented on LLY. Rothschild & Co Redburn raised their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. Cantor Fitzgerald raised their price objective on shares of Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Wednesday, March 18th. Finally, Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a report on Thursday, May 21st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,227.74.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Insider Monkey highlighted Eli Lilly as one of billionaire Ken Fisher’s top high-growth stock picks, a vote of confidence that may reinforce the market’s view that LLY remains a high-quality growth name. Billionaire Ken Fisher’s Top 5 High-Growth Stock Picks
• Positive Sentiment: Shares could benefit from a PRNewswire update showing Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death in a Phase 3 CLL/SLL trial, suggesting Lilly’s pipeline has catalysts beyond obesity drugs. Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk…
• Positive Sentiment: A Yahoo Finance article noted that Lilly’s newer JAK2 inhibitor data supports the idea that the company has broader growth drivers and possible upside beyond its obesity franchise. Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside
• Neutral Sentiment: Multiple articles repeated the same bullish thesis that investors still like Eli Lilly for its strong growth, but some are questioning whether the stock’s valuation leaves less room for near-term upside. Should You Buy Eli Lilly Stock Now or Wait for a Dip?
• Negative Sentiment: That same valuation concern could weigh on the stock, since analysts and commentators continue to describe LLY as expensive even after its strong operating performance. Should You Buy Eli Lilly Stock Now or Wait for a Dip?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.